It is made available under a CC-BY-NC-ND 4.0 International license .

| 1 | Lower Omega-3 Status Associated with Higher Erythrocyte Distribution Width and Neutrophil- |
|----|--|
| 2 | Lymphocyte Ratio in UK Biobank Cohort |
| 3 | Michael I. McBurney ¹⁻³ , Nathan L. Tintle ^{1,4} , William S. Harris ^{1,5} |
| 4 | ¹ Fatty Acid Research Institute, Sioux Falls, SD 57106, USA (MIM, NLT, WSH); ² Department of Human |
| 5 | Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada (MIM), ³ Division of |
| 6 | Biochemical and Molecular Biology, Friedman School of Nutrition Science and Policy, Tufts University, |
| 7 | Boston, MA 02111, USA (MIM); 4 Department of Population Health Nursing Science, College of Nursing, |
| 8 | University of Illinois – Chicago, Chicago, IL 60612, USA(NLT); ⁵ Sanford School of Medicine, University of |
| 9 | South Dakota, Sioux Falls, SD 57105, USA (WSH). |
| 10 | Authors last names: McBurney, Tintle, Harris |
| 11 | Corresponding author: M.I. McBurney, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail: |
| 12 | mim@faresinst.com |
| 13 | Reprint requests: W.S. Harris, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail: |
| 14 | wsh@faresinst.com |
| 15 | Sources of Support: This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non- |
| 16 | profit foundation bringing together nutrition scientists and biostatistical experts to accelerate discovery |
| 17 | of the relationships between fatty acids, especially omega-3 fatty acids, and health. Analytic code will be |
| 18 | made available upon request to the Fatty Acid Research Institute (<u>https://www.faresinst.org/</u>). |
| 19 | Running Title: Omega-3 Fatty Acids and Hematological Indices |
| 20 | Abbreviations: BMI, body mass index; CRP, high-sensitivity C-reactive protein; DHA, docosahexaenoic |
| 21 | acid; eO31, estimated omega-3 index; EPA, eicosapentaenoic acid; Hb, hemoglobin; Omega3%, total |
| 22 | omega-3 fatty acid; NLR, neutrophil-lymphocyte ratio; O3I, omega-3 index; NMR, nuclear magnetic |
| 23 | resonance; RDW, red blood cell distribution width. |
| 27 | |

It is made available under a CC-BY-NC-ND 4.0 International license .

25 Abstract

| 26 | High red blood distribution width (RDW) is associated with decreased red blood cell deformability, and |
|----|--|
| 27 | high neutrophil-lymphocyte ratio (NLR) is a biomarker of systemic inflammation and innate-adaptive |
| 28 | immune system imbalance. Both RDW and NLR are predictors of chronic disease risk and mortality. |
| 29 | Omega-3 index (O3I) values have previously been shown to be inversely associated with RDW and NLR |
| 30 | levels. Our objective was to determine if total plasma long chain omega-3 fatty acids (Omega3%) |
| 31 | measured in the UK Biobank cohort were associated with RDW and NLR values. RDW- and NLR- |
| 32 | relationships with Omega3% were characterized in 109,191 adults (58.4% female). RDW- and NLR- |
| 33 | Omega3% relationships were inversely associated with Omega3% (both p<0.0001). These cross-sectional |
| 34 | associations confirm previous findings that increasing RDW and NLR values are associated with low O3I. |
| 35 | The hypothesis that RDW and/or NLR values can be reduced in individuals with less-than optimal long |
| 36 | chain omega 3 values need to be tested in randomized controlled intervention trials using EPA and/or |
| 37 | DHA. |
| 38 | |
| 39 | Keywords: erythrocytes, neutrophil-lymphocyte ratio, red blood cell distribution width, long chain |

40 omega-3 fatty acids.

It is made available under a CC-BY-NC-ND 4.0 International license .

42 Introduction

| 43 | A complete blood count is a routine component of medical exams that provides comprehensive |
|----|---|
| 44 | hematologic information. Using standardized reference ranges, healthy individuals can be distinguished |
| 45 | from those with nutrient deficiencies, infections, tissue damage, and inflammation. In addition to basic |
| 46 | information provided by hemoglobin, hematocrit, and platelet and white blood cell counts, the red |
| 47 | blood cell distribution width (RDW) is routinely used to diagnose anemias [1] and may be useful to |
| 48 | assess overall wellness [2]. Another metric, the neutrophil-to-lymphocyte ratio (NLR), a measure of |
| 49 | innate-adaptive immune balance, is used to monitor inflammation and immunity [3–6]. Risk of non- |
| 50 | communicable disease and mortality has been associated with elevated RDW (Table 1) and NLR values |
| 51 | (Table 2). |
| 52 | The long-chain omega-3 fatty acid (Omega3%) composition of all cell membranes (including blood |
| 53 | cells) affects physicochemical properties such as fluidity, membrane protein function, signaling cascades, |
| 54 | overall cell function and ultimately, host physiology [7–9]. The EPA DHA content of RBC membranes, i.e., |
| 55 | the Omega-3 Index (O3I) [10], reflects long-term dietary omega-3 intake [11] and the EPA+DHA |
| 56 | composition of major organs [12]. Optimal O3I levels for cardiovascular health appear to be >8% [13]. |
| 57 | O3I is predictive of risk of total mortality in individuals without prevalent cardiovascular disease [14] and |
| 58 | associated with mortality risk before and after adjustment for individual n-6 fatty acids, whether in |
| 59 | aggregate, by carbon-chain groups, or individually [15]. A harmonized, de novo analysis of over 42,000 |
| 60 | individuals prospectively followed for over 16 years, with over 15,000 deaths observed, found risk for |
| 61 | total mortality was 15-18% lower in the highest vs lowest quintile for long chain omega-3 fatty acids and |
| 62 | similar relationships were observed for death from cardiovascular disease and cancer [16]. Increased |
| 63 | dietary long chain omega-3 fatty acid intake increases red blood cell deformability [17–20], and frequent |
| 64 | fish consumption is associated with lower NLR [21]. |

It is made available under a CC-BY-NC-ND 4.0 International license .

65 In previous studies using a clinical US laboratory database, a low O3I was inversely associated with

66 RDW [22] and NLR [23]. The present study aims to confirm reported RDW and NLR relationships with

67 Omega3% in a large and well-characterized cohort from the UK.

68 Methods

69 Sample:

The UK Biobank is a prospective, population-based cohort of 502,639 individuals, aged 40-69y,
recruited between April 2007 and December 2010 [24,25]. Total long chain omega-3 fatty acids

72 (Omega3%) and DHA (DHA%) were measured in plasma as a percent of total fatty acids by nuclear

73 magnetic resonance (NMR, Nightingale Health Plc, Helsinki, Finland) [26] at enrollment. Within the

cohort, 117,351 adults ≥18y had data available for Omega3% and DHA%, and 109,191 also had complete

75 data on RDW, neutrophil count, lymphocyte count, NLR, age, sex, body mass index (BMI), high-

sensitivity C-reactive protein (CRP), and hemoglobin (Hb) (Figure 1). Since O3I was not measured in the

77 UK Biobank, the O3I was calculated from Omega3% using the method of Schuchardt et al [27]. UK

78 Biobank has ethical approval (Ref. 11/NW/0382) from the Northwest Multi-centre Research Ethics

79 Committee as a Research Tissue Bank (RTB). All participants gave electronic signed informed consent.

80 The UK Biobank study was conducted according to the guidelines laid down in the Declaration of

81 Helsinki. The UK Biobank protocol is available online (<u>http://www.ukbiobank.ac.uk/wp114</u>

82 <u>content/uploads/2011/11/UK-Biobank-Protocol.pdf</u>). The University of South Dakota Institutional

83 Review Board reviewed and approved the use of de-identified data for research purposes (IRB-21-147).

84 Statistical methods

85 Sample characteristics are summarized using standard statistical methods (e.g., means, SDs,

86 correlations) with t-tests. Unadjusted linear models (Model 1) were used to predict RDW and NLR values

by cubic splines of Omega3% and DHA%. Model 2 adjusted for sex, age, BMI, CRP and Hb values for

It is made available under a CC-BY-NC-ND 4.0 International license .

- 88 RDW and for sex, age, BMI, and CRP for NLR. Pearson correlations were used to assess the strength and
- 89 direction of linear association between covariates and RDW or NLR. Statistical significance was set to
- 90 0.05 for all analyses and 95% confidence bands are provided where appropriate.
- 91
- 92 Results
- 93 Dietary determinants of Omega3% status have been published for the UK Biobank cohort [27].

94 Thirty-one percent of participants reported using fish oil supplements, and fatty fish were consumed by

- 95 56% of the cohort, factors contributing to a mean Omega3% of 4.42% (**Table 3**) and O3I = 5.59% [27]. In
- 96 this cohort of 109,191 individuals, the correlation between Omega3% and DHA% was r=0.88. Because
- 97 Omega3% and DHA% were so highly correlated, only the Omega3% results for Model 1 are presented in
- 98 the main text, with results for DHA% located in **Supplemental Figure 1**. Model 2 results for RDW- and
- 99 NLR-relationships with Omega3% and DHA% are also located in Supplemental Figures 2 and 3,
- 100 respectively.
- 101 RDW was significantly (p<0.0001) and inversely associated with Omega3% (Figure 2A). Adjustments
- 102 for age, sex, BMI, CRP and Hb (Model 2) did not significantly change the R² nor the shape of the
- 103 relationship (Supplemental Figure 2). Excluding 3,698 individuals with anemia (mean cell volume >100fL
- and/or Hb <13g/dL for males and Hb <12g/dL for females) as done by [22], did not significantly change
- 105 the R² for the RDW-Omega3% (data not presented).
- NLR was significantly (p<0.0001) and inversely associated with Omega3% (Figure 3A). Adjustments
 for age, sex, BMI and CRP (Model 2) did not significantly change the R² nor the shape of the relationship
 (Supplemental Figure 2). Excluding 24,559 individuals with evidence of inflammation, i.e., CRP >3 mg/L,
 as done by [23], did not significantly change NLR-Omega3% (data not presented).
- 110
- 111

It is made available under a CC-BY-NC-ND 4.0 International license .

112 Discussion

135

| 113 | In this study examining the UK Biobank cohort, we confirm previously reported inverse associations |
|-----|---|
| 114 | of long chain omega-3 fatty acid concentrations with RDW [22] (Figure 2) and NLR [23] (Figure 3). The |
| 115 | average estimated O3I of 5.59% in the UK Biobank cohort [27] is similar to that (~5.0%) reported in |
| 116 | healthy individuals globally [28,29]. The average RDW in the UK Biobank cohort (13.5%) is similar to |
| 117 | values (12.6-12.9%) reported in adults living in the US [30], including those free of cardiovascular disease |
| 118 | (NHANES 1994-2004) [31] and without clinical evidence of anemia or inflammation [22]. The UK Biobank |
| 119 | average NLR (2.36±1.20, Table 3) is similar to the ~2.2 of the US population [3,6] and a healthy cohort |
| 120 | without evidence of anemia or inflammation [23]. |
| 121 | Elevated RDW levels predict risk for several adverse health outcomes including death (Table 1). In |
| 122 | four studies of apparently healthy, free-living individuals, the highest RDW category (Cn; top 20-25% of |
| 123 | individuals) has an average HR=1.17 (vs C1) (Table 4) . Thus, the observed distribution of mean RDW |
| 124 | values across values of the Omega3% (13.85-13.40=0.45 units) (Figure 2A) corresponds to a HR = 1.06 or |
| 125 | a 6% increased risk of all-cause mortality associated with Omega3% when moving from the highest to |
| 126 | lowest observed Omega3% values. |
| 127 | An elevated NLR has been associated with increased risk of cardiovascular events, lower respiratory |
| 128 | disease, influenza, cancer, and mortality (Table 2). In two studies of free living, apparently healthy |
| 129 | individuals, the average HR for mortality in the highest NLR category (Cn; top 20-25% of individuals) vs |
| 130 | the lowest (C1) NLR (Table 5) was 1.43. As shown in Figure 3, there was a 0.7 difference in the mean NLR |
| 131 | (1.7 to 2.4) across the observed Omega3% range (Figure 3A), which is equivalent to a HR = 1.24 or a 24% |
| 132 | increased risk of all-cause mortality associated with Omega3% when moving from the highest to lowest |
| 133 | observed Omega3% values. |
| 134 | The primary strengths of this study are the large sample of free-living individuals and that blood |

samples for RDW, NLR, and Omega3% measurements were taken at the same time. Consistent with

It is made available under a CC-BY-NC-ND 4.0 International license .

| 136 | previous studies (Figures 2B and 3A) [22,23], monotonic inverse relationships were observed with long- |
|-----|---|
| 137 | chain omega-3 concentrations (Figures 2A and 3A). The higher RDW and NLR values observed in the UK |
| 138 | Biobank cohort may reflect a higher prevalence of inflammation (UKBB mean CRP= 2.60 ± 4.40 mg/L vs |
| 139 | Health Diagnostic Laboratory mean CRP=1.23 \pm 0.77 mg/L) and differences in age (UKBB mean age |
| 140 | =57.1 \pm 8.08 y vs Health Diagnostic Laboratory mean = 54.3 \pm 14.8 y). Among the limitations are the |
| 141 | unavailability of data on levels of other n-3 fatty acids ($lpha$ -linolenic acid, EPA, and n-3 docosapentaenoic |
| 142 | acid) and the potential for other unmeasured (or unconsidered) covariates that might have contributed |
| 143 | to the observed associations. The major weakness of this and previous studies [22,23] is their cross- |
| 144 | sectional natures which do not provide evidence of causality. |
| 145 | In conclusion, significant inverse relationships with RDW- and NLR- were identified with Omega3% |
| 146 | and DHA%. These observations in the UK Biobank cohort using a different analytical method, i.e. NMR, |
| 147 | confirm previously reported RDW- and NLR relationships with O3I, i.e. EPA+DHA [22,23]. We propose |
| 148 | that low Omega3% may indicate a state that is less resilient and/or more predisposed to disease. We |
| 149 | cautiously suggest that RDW- and NLR- relationships with Omega3% are clinically relevant and highly |
| 150 | recommend that randomized controlled intervention trials using EPA and/or DHA be conducted to |
| 151 | determine their effects on RDW and/or NLR values, particularly in individuals with less-than optimal long |
| 152 | chain omega 3 values at baseline. |
| 153 | |
| 154 | CRediT authorship contribution statement: Michael I. McBurney: Conceptualization, Writing – original |
| 155 | draft, Writing – review & editing. Nathan L. Tintle: Formal analysis, Writing -reviewing & editing. |
| 156 | William S. Harris: Conceptualization, Funding acquisition, Writing – review & editing. |
| 157 | |

Disclosures: M.I. McBurney has or has held consulting agreements in the past 3 years with the Council
 for Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences

It is made available under a CC-BY-NC-ND 4.0 International license .

- 160 Institute, North America; McCormick; PepsiCo; Smartech Topicals; and VitaMe Technologies. W.S. Harris
- 161 holds an interest in OmegaQuant Analytics, a lab that offers omega-3 blood testing; and is a member of
- 162 the RB Schiff Science and Innovation Advisory Board. N.L. Tintle has no conflicts to disclose.

163

It is made available under a CC-BY-NC-ND 4.0 International license .

165 **Citations**

- 166 [1] J.D. Bessman, P.R. Gilmer, F.H. Gardner, Improved Classification of Anemias by MCV and RDW, Am
- 167 J Clin Pathol. 80 (1983) 322–326. https://doi.org/10.1093/ajcp/80.3.322.
- 168 [2] L.C. Pilling, J.L. Atkins, M.O. Duff, R.N. Beaumont, S.E. Jones, J. Tyrrell, C.-L. Kuo, K.S. Ruth, M.A.
- 169 Tuke, H. Yaghootkar, A.R. Wood, A. Murray, M.N. Weedon, L.W. Harries, G.A. Kuchel, L. Ferrucci,
- 170 T.M. Frayling, D. Melzer, Red blood cell distribution width: Genetic evidence for aging pathways in
- 171 116,666 volunteers, PLoS ONE. 12 (2017) e0185083.
- 172 https://doi.org/10.1371/journal.pone.0185083.
- 173 [3] B. Azab, M. Camacho-Rivera, E. Taioli, Average Values and Racial Differences of Neutrophil
- 174 Lymphocyte Ratio among a Nationally Representative Sample of United States Subjects, PLoS ONE.
- 175 9 (2014) e112361. https://doi.org/10.1371/journal.pone.0112361.
- 176 [4] J. Li, Q. Chen, X. Luo, J. Hong, K. Pan, X. Lin, X. Liu, L. Zhou, H. Wang, Y. Xu, H. Li, C. Duan,
- 177 Neutrophil-to-lymphocyte ratio positively correlates to age in healthy population, J. Clin. Lab. Anal.
- 178 29 (2015) 437–443. https://doi.org/10.1002/jcla.21791.
- 179 [5] A.M. Paul, S.D. Mhatre, E. Cekanaviciute, A.-S. Schreurs, C.G.T. Tahimic, R.K. Globus, S. Anand, B.E.
- 180 Crucian, S. Bhattacharya, Neutrophil-to-lymphocyte ratio: A biomarker to monitor the immune
- 181 status of astronauts, Front. Immunol. 11 (2020) 564950.
- 182 https://doi.org/10.3389/fimmu.2020.564950.
- 183 [6] M. Song, B.I. Graubard, C.S. Rabkin, E.A. Engels, Neutrophil-to-lymphocyte ratio and mortality in
- the United States general population, Nature Res. 11 (2021) 464. https://doi.org/10.1038/s41598020-79431-7.
- 186 [7] T. Huber, K. Rajamoorthi, V.F. Kurze, K. Beyer, M.F. Brown, Structure of Docosahexaenoic Acid-
- 187 Containing Phospholipid Bilayers as Studied by 2H NMR and Molecular Dynamics Simulations, J.
- 188 Am. Chem. Soc. 124 (2002) 298–309. https://doi.org/10.1021/ja011383j.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 189 [8] H.F. Turk, R.S. Chapkin, Membrane lipid raft organization is uniquely modified by n-3
- 190 polyunsaturated fatty acids, PLEFA. 88 (2013) 43–47.
- 191 [9] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and
- 192 clinical relevance, Bioch. Biophys. Acta: Mol Cell Biol Lipids. 1851 (2015) 469–484.
- 193 https://doi.org/10.1016/j.bbalip.2014.08.010.
- 194 [10] W.S. Harris, C. von Schacky, The Omega-3 Index: a new risk factor for death from coronary heart
- 195 disease?, Prev. Med. 39 (2004) 212–220. https://doi.org/10.1016/j.ypmed.2004.02.030.
- 196 [11] K.H. Jackson, J.M. Polreis, N.L. Tintle, P.M. Kris-Etherton, W.S. Harris, Association of reported fish
- 197 intake and supplementation status with the omega-3 index, Prostaglandins, Leukotrienes and
- 198 Essential Fatty Acids. 142 (2019) 4–10. https://doi.org/10.1016/j.plefa.2019.01.002.
- 199 [12] J.I. Fenton, E.A. Gurzell, E.A. Davidson, W.S. Harris, Red blood cell PUFAs reflect the phospholipid
- 200 PUFA composition of major organs, Prostaglandins, Leukotrienes and Essential Fatty Acids. 112
- 201 (2016) 12–23. https://doi.org/10.1016/j.plefa.2016.06.004.
- 202 [13] W.S. Harris, The Omega-3 Index: Clinical Utility for Therapeutic Intervention, Curr Cardiol Rep. 12
- 203 (2010) 503–508. https://doi.org/10.1007/s11886-010-0141-6.
- 204 [14] M.I. McBurney, N.L. Tintle, R.S. Vasan, A. Sala-Vila, W.S. Harris, Using an erythrocyte fatty acid
- fingerprint to predict risk of all-cause mortality: the Framingham Offspring Cohort, The American
 Journal of Clinical Nutrition. (2021) ngab195. https://doi.org/10.1093/ajcn/ngab195.

207 [15] W. Harris, N. Tintle, V. Ramachandran, Erythrocyte n-6 fatty acids and risk for cardiovascular

- 208 outcomes and total mortality in the Framingham Heart Study, Nutrients. 10 (2018) 2012.
- 209 https://doi.org/10.3390/nu10122012.
- 210 [16] W.S. Harris, N.L. Tintle, F. Imamura, F. Qian, A.V. Ardisson Korat, M. Marklund, L. Djoussé, J.K.
- Bassett, P.-H. Carmichael, Y.-Y. Chen, Y. Hirakawa, L.K. Kupers, M. Lankinen, R.A. Murphy, C.
- 212 Samieri, M.K. Senn, P. Shi, J.K. Virtanen, I.A. Brouwer, K.-L. Chien, G. Eiriksdottir, N.G. Forouhi, J.M.

- 213 Geleijnse, G.G. Giles, V. Gudnason, C. Helmer, A. Hodge, R. Jackson, K.-T. Khaw, M. Laakso, H. Lai,
- D. Laurin, J. Lindsay, R. Micha, J. Mursu, T. Ninomiya, W. Post, B.M. Psaty, U. Riserus, J.G.
- 215 Robinson, A.H. Shadyab, L. Snetselaar, A. Sala-Vila, Y. Sun, L.M. Steffen, M.Y. Tsai, N.J. Wareham,
- A.C. Wood, J.H.Y. Wu, F. Hu, Q. Sun, D.S. Siscovick, R.N. Lemaitre, D. Mozaffarian, F. The Fatty
- Acids and Outcomes Research Consortium, Blood n-3 fatty acid levels and total and cause-specific
- 218 mortality from 17 prospective studies, Nature Commun. 12 (2021) 1–9.
- 219 https://doi.org/10.1038/s41467-021-22370-2.
- 220 [17] T. Terano, A. Hirai, T. Hamazaki, S. Kobayashi, T. Fujita, Y. Tamura, A. Kumagai, Effect of oral
- administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and
- red cell deformability in healthy human subjects, Atherosclerosis. 46 (1983) 321–331.
- [18] I.J. Cartwright, A.G. Pockley, J.H. Galloway, M. Greaves, F.E. Preston, The effects of dietary omega-
- 3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability
 and blood viscosity in healthy volunteers, Atherosclerosis. 55 (1985) 267–281.
- 226 [19] R. Bach, U. Schmidt, F. Jung, H. Kiesewetter, B. Hennen, E. Wenzel, H. Schieffer, L. Bette, S.
- 227 Heyden, Effects of Fish Oil Capsules in Two Dosages on Blood Pressure, Platelet Functions,
- Haemorheological and Clinical Chemistry Parameters in Apparently Healthy Subjects, Ann Nutr
- 229 Metab. 33 (1989) 359–367. https://doi.org/10.1159/000177559.
- [20] E. Hessel, J.J. Agren, M. Paulitschke, O. Hanninen, A. Hanninen, D. Lerche, Freshwater fish diet
- affects lipid composition, deformability and aggregation properties of erythrocytes,
- 232 Atherosclerosis. 82 (1990) 37–42.
- [21] S. Tani, R. Matsuo, W. Atsumi, K. Kawauchi, T. Ashida, T. Yagi, K. Imatake, Y. Suzuki, A. Takahashi,
- 234 N. Matsumoto, Y. Okumura, Higher frequency of fish intake may be associated with a lower
- neutrophil/lymphocyte ratio: Anti-atherosclerotic effects of fish consumption, Ann Nutr Metab.
- 236 (2021) 1–8. https://doi.org/10.1159/000515915.

It is made available under a CC-BY-NC-ND 4.0 International license .

- [22] M.I. McBurney, N.L. Tintle, W.S. Harris, Omega-3 index is directly associated with a healthy red
- blood cell distribution width, Prostaglandins, Leukotrienes and Essential Fatty Acids. 176 (2022)
- 239 102376. https://doi.org/10.1016/j.plefa.2021.102376.
- [23] M.I. McBurney, N.L. Tintle, W.S. Harris, The omega-3 index is inversely associated with the
- neutrophil-lymphocyte ratio in adults', Prostaglandins, Leukotrienes and Essential Fatty Acids. 177
- 242 (2022) 102397. https://doi.org/10.1016/j.plefa.2022.102397.
- [24] C. Sudlow, J. Gallacher, N. Allen, V. Beral, P. Burton, J. Danesh, P. Downey, P. Elliott, J. Green, M.
- Landray, B. Liu, P. Matthews, G. Ong, J. Pell, A. Silman, A. Young, T. Sprosen, T. Peakman, R. Collins,
- 245 UK Biobank: An open access resource for identifying the causes of a wide range of complex
- diseases of middle and old age, PLoS Med. 12 (2015) e1001779.
- 247 https://doi.org/10.1371/journal.pmed.1001779.
- 248 [25] H. Julkunen, A. Cichońska, P.E. Slagboom, P. Würtz, Nightingale Health UK Biobank Initiative,
- 249 Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-
- 250 19 in the general population, ELife. 10 (2021) e63033. https://doi.org/10.7554/eLife.63033.
- 251 [26] P. Wurtz, J.R. Raiko, C.G. Magnussen, P. Soininen, A.J. Kangas, T. Tynkkynen, R. Thomson, R.
- 252 Laatikainen, M.J. Savolainen, J. Laurikka, P. Kuukasjarvi, M. Tarkka, P.J. Karhunen, A. Jula, J.S.
- 253 Viikari, M. Kahonen, T. Lehtimaki, M. Juonala, M. Ala-Korpela, O.T. Raitakari, High-throughput
- 254 quantification of circulating metabolites improves prediction of subclinical atherosclerosis,

255 European Heart Journal. 33 (2012) 2307–2316. https://doi.org/10.1093/eurheartj/ehs020.

- [27] J.P. Schuchardt, N. Tintle, J. Westra, W.S. Harris, Estimation and predictors of the Omega-3 Index in
 the UK Biobank, Br J Nutr. (2022) 1–40. https://doi.org/10.1017/S0007114522003282.
- 258 [28] J.P. Schuchardt, M. Cerrato, M. Ceseri, L.F. DeFina, G.E. Delgado, S. Gellert, A. Hahn, B.V. Howard,
- A. Kadota, M.E. Kleber, R. Latini, W. Maerz, J.E. Manson, S. Mora, Y. Park, A. Sala-Vila, C. von
- 260 Schacky, A. Sekikawa, N. Tintle, K.L. Tucker, R.S. Vasan, W.S. Harris, Red blood cell fatty acid

- 261 patterns from 7 countries: Focus on the Omega-3 index, Prostaglandins, Leukotrienes and Essential
- 262 Fatty Acids. 179 (2022) 102418. https://doi.org/10.1016/j.plefa.2022.102418.
- 263 [29] K.D. Stark, M.E. Van Elswyk, M.R. Higgins, C.A. Weatherford, N. Salem, Global survey of the omega-
- 264 3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy
- adults, Prog. Lipid Res. 63 (2016) 132–152. https://doi.org/10.1016/j.plipres.2016.05.001.
- 266 [30] J.M. Crook, A.L. Horgas, S.L. Yoon, O. Grundmann, V. Johnson-Mallard, Vitamin C Plasma Levels
- Associated with Inflammatory Biomarkers, CRP and RDW: Results from the NHANES 2003–2006
- 268 Surveys, Nutrients. 14 (2022) 1254. https://doi.org/10.3390/nu14061254.
- 269 [31] V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red cell
- 270 distribution width and high sensitivity C-reactive protein for coronary heart disease mortality
- 271 prediction in multi-ethnic population: Findings from the 1999–2004 NHANES, Int. J. Cardiol. 168
- 272 (2013) 5156–5161. https://doi.org/10.1016/j.ijcard.2013.07.109.
- [32] Q. Li, X. Chen, B. Han, Red blood cell distribution width is associated with frailty in older inpatients
- in China: Sex differences in a cross-sectional study, Experimental Gerontology. 150 (2021) 111392.
- 275 https://doi.org/10.1016/j.exger.2021.111392.
- [33] E.M. Hald, M.-L. Løchen, J. Lappegård, T.S. Ellingsen, E.B. Mathiesen, T. Wilsgaard, I. Njølstad, S.K.
- 277 Brækkan, J.-B. Hansen, Red Cell Distribution Width and Risk of Atrial Fibrillation and Subsequent
- 278 Thromboembolism: The Tromsø Study, TH Open. 04 (2020) e280–e287. https://doi.org/10.1055/s-
- 0040-1716417.
- 280 [34] H.-M. Yao, T.-W. Sun, X.-J. Zhang, D.-L. Shen, Y.-Y. Du, Y.-D. Wan, J.-Y. Zhang, L. Li, L.-S. Zhao, Red
- 281 blood cell distribution width and long-term outcome in patients undergoing percutaneous
- coronary intervention in the drug-eluting stenting era: A two-year cohort study, PLoS ONE. 9
- 283 (2014) e94887. https://doi.org/10.1371/journal.pone.0094887.

- 284 [35] T. Osadnik, J. Strzelczyk, M. Hawranek, A. Lekston, J. Wasilewski, A. Kurek, A.R. Gutowski, K.
- 285 Wilczek, K. Dyrbuś, M. Gierlotka, A. Wiczkowski, M. Gąsior, A. Szafranek, L. Poloński, Red cell
- distribution width is associated with long-term prognosis in patients with stable coronary artery
- 287 disease, BMC Cardiovasc Disord. 13 (2013) 113. https://doi.org/10.1186/1471-2261-13-113.
- [36] S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, J.K. Ghali, Gender and Ethnic Differences in
- 289 Red Cell Distribution Width and Its Association With Mortality Among Low Risk Healthy United
- 290 State Adults, The American Journal of Cardiology. 109 (2012) 1664–1670.
- 291 https://doi.org/10.1016/j.amjcard.2012.01.396.
- [37] S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, Red cell distribution width and risk of
- 293 peripheral artery disease: Analysis of National Health and Nutrition Examination Survey 1999–
- 294 2004, Vasc Med. 17 (2012) 155–163. https://doi.org/10.1177/1358863X12442443.
- [38] T.S. Perlstein, J. Weuve, M.A. Pfeffer, J.A. Beckman, Red blood cell distribution width and mortality
- risk in a community-based prospective cohort, Arch Intern Med. 169 (2009) 588.
- 297 https://doi.org/10.1001/archinternmed.2009.55.
- 298 [39] K.V. Patel, L. Ferrucci, W.B. Ershler, D.L. Longo, J.M. Guralnik, Red blood cell distribution width and
- the risk of death in middle-aged and older adults, Arch Intern Med. 169 (2009) 515.
- 300 https://doi.org/10.1001/archinternmed.2009.11.
- 301 [40] J. Guo, H. Zhang, Y. Li, M. Hao, G. Shi, J. Wang, Z. Wang, X. Wang, Neutrophil-lymphocyte ratio as a
- 302 predictor of slow gait speed in older adults: The Rugao Longitudinal Aging Study, Experimental
- 303 Gerontology. 152 (2021) 111439. https://doi.org/10.1016/j.exger.2021.111439.
- 304 [41] N.H. Adamstein, J.G. MacFadyen, L.M. Rose, R.J. Glynn, A.K. Dey, P. Libby, I.A. Tabas, N.N. Mehta,
- 305 P.M. Ridker, The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from
- five contemporary randomized trials, European Heart Journal. 42 (2021) 896–903.
- 307 https://doi.org/10.1093/eurheartj/ehaa1034.

It is made available under a CC-BY-NC-ND 4.0 International license .

| 308 42 H. Wada, T. Doni, K. Miyauchi, R. Nishio, M. Takeuchi, N. Takanashi, H. Endo, |), IVI. Ugita, H. | Iwata, I |
|--|-------------------|----------|
|--|-------------------|----------|

- 309 Kasai, S. Okazaki, K. Isoda, S. Suwa, H. Daida, Neutrophil to lymphocyte ratio and long-term
- 310 cardiovascular outcomes in coronary artery disease patients with low high-sensitivity C-reactive

311 protein level, Int. Heart J. 61 (2020) 447–453. https://doi.org/10.1536/ihj.19-543.

- 312 [43] J.-H. Liu, Y.-J. Zhang, Q.-H. Ma, H.-P. Sun, Y. Xu, C.-W. Pan, Elevated blood neutrophil to
- 313 lymphocyte ratio in older adults with cognitive impairment, Archives of Gerontology and
- 314 Geriatrics. 88 (2020) 104041. https://doi.org/10.1016/j.archger.2020.104041.
- 315 [44] J. Fest, T.R. Ruiter, B. Groot Koerkamp, D. Rizopoulos, M.A. Ikram, C.H.J. van Eijck, B.H. Stricker,
- 316 The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The
- 317 Rotterdam Study, Eur J Epidemiol. 34 (2019) 463–470. https://doi.org/10.1007/s10654-018-0472-
- 318 y.
- 319 [45] B. Suh, D.W. Shin, H.-M. Kwon, J.M. Yun, H.-K. Yang, E. Ahn, H. Lee, J.H. Park, B. Cho, Elevated
- neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy adults, PLoS ONE. 12
- 321 (2017) e0183706. https://doi.org/10.1371/journal.pone.0183706.
- 322
- 323

| | | | | | | Quantile of RDW | | | | | |
|--------------------------------------|---|--|--------|---------|--------------|------------------|--------|---|------------------------|-----------------|---------------------|
| Outcome | Population | Study | n | 1 | 2 | 3 | 4 | 5 | OR or HR (95% Cl) | p-value | Citati |
| Frailty | Hospitalized men, ≥60y | Comprehensive tertiary hospital in mainland China | 334 | ≤12.6% | 12.6-13.1% | 13.1-13.7% | >13.7% | | OR=1.14 (1.05-1.24) | 0.002 | [32 |
| Frailty | Hospitalized women, ≥60y | Comprehensive tertiary hospital in mainland China | 285 | ≤12.6% | 12.6-13.1% | 13.1-13.7% | >13.7% | | OR=1.27 (1.16-1.38) | <0.001 | [32 |
| Incident atrial fibrillation (AF) | Adults ≥25y | inhabitants of Tromso, Norway | 26,111 | <12.3% | 12.4-12.7% | 12.8-13.2% | ≥13.3% | | HR=1.08 (1.03-1.12) | Not reported | t is mad |
| Venous thromboembolism | Adults with AF ≥25y | inhabitants of Tromso, Norway | 1,812 | <12.7% | 12-8-13.3% | >13.3% | | | HR=1.09 (0.83-1.41) | Not reported | de ≌vail |
| Ischemic stroke | Adults with AF ≥25y | inhabitants of Tromso, Norway | 1,812 | <12.7% | 12.8-13.3% | >13.3% | | | HR=1.18 (1.03-1.34) | Not reported | ab <u>te</u> ur |
| In-hospital mortality | Patients without anemia who underwent percutaneous coronary intervention (PCI) | Affiliated hospital of Zhengzhou University, China | 2,169 | <12.27% | 12.27-≤13.0% | >13-<13.5% | ≥13.5% | | HR=1.4 (1.23-1.59) | 0.000 | nder a CCBY-NC-NE |
| All-cause mortality | Patients with stable coronary artery disease undergoing stent implantation | Silesian Centre for Heart Diseases, Poland | 2,033 | <13.1% | 13.1-<13.6% | 13.6-<14.1% | ≥14.1% | | HR=1.23 (1.13-1.35) | <0.0001 | 0 4.0 International |
| All deaths, men | Adults ≥20y without diabetes or CV | NHANES 1988- 1994, USA | 7,201 | ≤12.4% | >12.4-≤12.9% | >12.9- ≤13.5% | >13.5% | | HR=1.21 (1.18-1.25) | <0.001 | lice 13e . |
| All deaths, women | Adults ≥20y without diabetes or previous CV | NHANES 1988- 1994, USA | 8,259 | ≤12.4% | >12.4-≤12.9% | >12.9- ≤13.5% | >13.5% | | HR=1.19 (1.14-1.24) | <0.001 | [36 |
| All CV deaths, men | Adults ≥20y without diabetes or previous CV | NHANES 1988- 1994, USA | 7,201 | ≤12.4% | >12.4-≤12.9% | >12.9- ≤13.5% | >13.5% | | HR=1.19 (1.14-1.25) | <0.001 | [36 |
| All CV deaths, women | Adults ≥20y without diabetes or previous CV | NHANES 1988- 1994, USA | 8,259 | ≤12.4% | >12.4-≤12.9% | >12.9- ≤13.5% | >13.5% | | HR=1.19 (1.12-1.26) | <0.001 | [36 |

| Coronary heart disease (CHD) deaths, men | Adults ≥20y without diabetes or previous CV | NHANES 1988- 1994, USA | 7,201 | ≤12.4% | >12.4-≤12.9% | >12.9- ≤13.5% | >13.5% | | HR=1.20 (1.12-1.28) | <0.001 | [36]prepri |
|---|---|---------------------------|--------|---------|------------------|------------------|--------------|---------|------------------------|--------|--|
| CHD deaths, women | Adults ≥20y without diabetes or previous CV | NHANES 1988- 1994, USA | 8,259 | ≤12.4% | >12.4-≤12.9% | >12.9- ≤13.5% | >13.5% | | HR=1.20 (1.11-1.29) | <0.001 | [36] |
| Peripheral artery disease | Adults ≥40y | NHANES 1999- 2004, USA | 6,950 | <12.2% | 12.3-12.5% | 12.6-13.1% | >13.1% | | HR=1.23 (1.14-1.33) | <0.001 | [37] |
| All-cause mortality | Adults ≥40y | NHANES 1988- 1994, USA | 15,852 | <12.35% | 12.5-12.65% | 12.8-13.15% | 13.2-13.75% | ≥13.80% | HR=1.27 (1.21-1.33) | <0.001 | [38] |
| CV mortality | Adults ≥40y | NHANES 1988- 1994, USA | 15,852 | <12.35% | 12.5-12.65% | 12.8-13.15% | 13.2-13.75% | ≥13.80% | HR=1.26 (1.19-1.33) | <0.001 | [38] <mark>ed</mark> |
| Cancer mortality | Adults ≥40y | NHANES 1988- 1994, USA | 15,582 | <12.35% | 12.5-12.65% | 12.8-13.15% | 13.2-13.75% | ≥13.80% | HR=1.30 (1.22-1.39) | <0.001 | t ister n |
| Chronic lower respiratory tract disease mortality | Adults ≥40y | NHANES 1988- 1994, USA | 15,582 | <12.35% | 12.5-12.65% | 12.8-13.15% | 13.2-13.75% | ≥13.80% | HR=1.36 (1.29-1.51) | 0.03 | eview) is t 80 de a <u>M</u> ailab |
| All-cause mortality | Adults ≥45y | NHANES 1988- 1994, USA | 8,175 | <12.55% | 12.55- 12.95% | 13.0-13.4% | 13.45-14.05% | >14.05% | HR=1.22 (1.15-1.30) | <0.001 | he auth |
| | | | | | | | | | | | or/funder, who has granted medRxiv a licens r a CC-BY-NC-ND 4.0 International license . |

Table 2. Odds Ratio (OR) or Hazards Ratio (HR) per increase in neutrophil-lymphocyte ratio (NLR) with respect to clinical outcome.

| Outcome | Population | Study | | | | Quantiles | of NLR | | | | | |
|---|--|--|--------|-------|-----------------|-----------------|--------|---|---|--|---------|----------|
| Outcome | | | n | 1 | 2 | 3 | 4 | 5 | 6 | OR or HR | p-value | Citation |
| Slow gait | Adults ≥70y | Rugao Longitudinal Aging Study, China | 1,753 | ≤1.29 | >1.29- ≤1.79 | >1.79- ≤2.36 | >2.36 | | | OR ¹ =2.73 (1.60- 4.68) | <0.001 | [40] |
| All-cause mortality | Adults ≥30y | NHANES 1999-2014, USA | 32,454 | <1.54 | 1.54-2.00 | 2.01-2.67 | >2.67 | | | HR ² =1.14 (1.10- 1.17) | <0.0001 | [6] |
| Heart disease mortality | Adults ≥30y | NHANES 1999-2014, USA | 900 | <1.54 | 1.54-2.00 | 2.01-2.67 | >2.67 | | | HR ² =1.17 (1.06- 1.29) | 0.002 | [6] |
| Chronic lower respiratory disease mortality | Adults ≥30y | NHANES 1999-2014, USA | 197 | <1.54 | 1.54-2.00 | 2.01-2.67 | >2.67 | | | HR ² =1.24 (1.04- 1.47) | 0.02 | [6] |
| Influenza/pneumonia mortality | Adults ≥30y | NHANES 1999-2014, USA | 82 | <1.54 | 1.54-2.00 | 2.01-2.67 | >2.67 | | | HR ² =1.26 (1.03- 1.54) | 0.03 | [6] |
| Kidney disease mortality | Adults ≥30y | NHANES 1999-2014, USA | 89 | <1.54 | 1.54-2.00 | 2.01-2.67 | >2.67 | | | HR ² =1.62 (1.21- 2.17) | 0.001 | [6] |
| All-cause mortality in individuals with prior myocardial infarction (MI), CANTOS | Adults with prior myocardial infarction (MI) and CRP ≥2mg/L | Canakinumab Thrombosis Outcomes Study (CANTOS) | 10,061 | ≤1.81 | 1.81-≤2.36 | 2.37-≤3.08 | >3.08 | | | HR ² = 1.36 (1.30- 1.46) | <0.0001 | [41] |
| Cardiovascular (CV) death, CANTOS | Adults with prior myocardial infarction (MI) and CRP ≥2mg/L | Canakinumab Thrombosis Outcomes Study (CANTOS) | 10,061 | ≤1.81 | 1.81-≤2.36 | 2.37-≤3.08 | >3.08 | | | 1.36 ² (1.27- 1.46) | <0.0001 | [41] |
| Major adverse cardiovascular event (MACE): non-fatal | Adults with prior myocardial | Canakinumab Thrombosis Outcomes | 10,061 | ≤1.81 | 1.81-≤2.36 | 2.37-≤3.08 | >3.08 | | | HR ² =1.22 (1.16- 1.28) | <0.0001 | [41] |

| MI, non-fatal stroke or CV death | infarction (MI) and CRP ≥2mg/L | Study (CANTOS) | | | | | | | | |
|---|---|--|--------|-------|------------|------------|-------|--|---------|------|
| MACE + hospitalization of unstable angina requiring urgent revascularization (MACE+) | Adults with prior myocardial infarction (MI) and CRP ≥2mg/L | Canakinumab Thrombosis Outcomes Study (CANTOS) | 10,061 | ≤1.81 | 1.81-≤2.36 | 2.37-≤3.08 | >3.08 | HR ² = 1.20 (1.14- 1.25) | <0.0001 | [41] |
| MACE+ | Healthy patients with LDL-C <130mg/dL and CRP ≥2mg/L | Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) | 17,802 | ≤1.58 | 1.58-≤2.10 | 2.10-≤2.75 | >2.75 | HR ² =1.11 (1.01- 1.22) | 0.03 | [41] |
| MACE+ | Patients with prior CV event and LDL-C ≥70mg/dL | PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE- 1) | 16,819 | ≤1.72 | 1.72-≤2.24 | 2.24-≤2.93 | >2.93 | HR ² =1.31 (1.14- 1.49) | 0.00007 | [41] |
| MACE+ | Patients with prior CV event and LDL-C ≥100mg/dL | PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE- 2) | 10,621 | ≤1.67 | 1.67-≤2.16 | 2.16-≤2.83 | >2.83 | HR ² =1.27 (1.12- 1.43) | 0.0002 | [41] |
| MACE+ | Patients with previous MI or multi-vessel coronary disease and either type 2 diabetes or metabolic syndrome | Cardiovascular Inflammation Reduction Trial (CIRT) | 4,768 | ≤1.73 | 1.73-≤2.27 | 2.27-≤2.96 | >2.96 | HR ² =1.09 (1.00- 1.20) | 0.045 | [41] |

medRxiv preprint doi: https://doi.org/10.1101/2022.12.09.22283290; this version posted December 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

| CV events: CV death, non-fatal MI, and non-fatal stroke | Patients with coroanry artery disease who underwent elective percutaneous coronary intervention (PCI) | Juntendo University Hospital, Japan | 1,951 | <1.5 | 1.5-1.9 | 1.9-2.5 | ≥2.5 | | | HR ¹ =1.85 (1.19- 2.88) | 0.007 | [42] |
|--|--|--|--------|----------|-----------------|-----------------|---------------|--------------|------|--|--------|------|
| Cognitive impairment | Adults ≥60y, community dwelling | Weitang Geriatric Diseases Study, China | 4,579 | <1.535 | 1.535- 2.022 | 2.023- 2.641 | >2.641 | | | HR ³ =1.11 (1.03- 1.20) | 0.02 | [43] |
| All-cause mortality | Adults ≥45y, community dwelling | Rotterdam Study, The Netherlands | 8,715 | <1.30 | 1.30-1.59 | 1.60-1.91 | 1.92- 2.41 | >2.41 | | HR ⁴ =1.64 (1.44- 1.86) | <0.001 | [44] |
| Ischemic stroke | Adults, 30-75y, undergoing general health screening | Seoul National University Hospital, Korea | 24,708 | <1.5 | 1.5-<2.0 | 2.0-<2.5 | 2.5-<3.0 | 3.0- <3.5 | >3.5 | HR ⁴ =2.96 (1.57- 5.58) | <0.001 | [45] |
| ¹ per 1 unit increase in logNLR. ² Per category increase | e in NLR. | | | <u> </u> | | | | | | | | |

³ per SD increase in logNLR.

⁴ comparing highest

vs lowest quartile

| It is made available under a CC-BY-INC-IND 4.0 International lic |
|--|
|--|

| Table 3. Variable distributions (Mean±SD) for entire UK Biobank cohort. | | | | | | | |
|--|------------------|-------------------------|---------------------------|--|--|--|--|
| Variable | All ¹ | All ¹ Female | | | | | |
| n | 101,191 | 59,113 | 50,078 | | | | |
| DHA, % | 2.01±0.68 | 2.12±0.66 | 1.88±0.68 ³²⁹ | | | | |
| Omega3, % | 4.42 (1.56) | 4.6 (1.58) | 4.21 (1.5) | | | | |
| RDW % | 13.49±0.98 | 13.32±1.05 | 13.45±0.89 ³³⁰ | | | | |
| NLR | 2.36±1.20 | 2.26±1.09 | 2.48±1.31 | | | | |
| Neutrophil, 10 ³ /µL | 4.22±1.42 | 4.19±1.40 | 4.26±1.45 | | | | |
| Lymphocyte, 10 ³ /µL | 1.96±1.04 | 2.01±0.89 | 1.90±1.19 ₃₃₂ | | | | |
| Age, y | 57.06±8.08 | 56.89±7.98 | 57.27±8.19 | | | | |
| BMI, kg/m ² | 27.42±4.77 | 27.08±5.15 | 27.84±4.23333 | | | | |
| CRP, mg/L | 2.60±4.40 | 2.69±4.33 | 2.49±4.49 | | | | |
| Deprivation Score ² | -1.33±3.09 | -1.36±3.04 | -1.29±3.14 ³³⁴ | | | | |
| Hb, g/dL | 14.17±1.24 | 13.49±0.96 | 14.98±1.03 | | | | |
| ¹ Based on self-identified social construct for race: 94.58% White, 0.57% Black, 1.91% Asian, and 2.94% | | | | | | | |
| Other. 336 | | | | | | | |

² With the exception of number (n), variable means are statistically different between females and males, p<0.0001. 337

338

Table 4. Mortality Hazard Ratio (HR) comparing the highest (top 20-25% of individuals) and lowest (bottom 20-25% of individuals) categories in red blood cell distribution width (RDW) in apparently healthy, free-living individuals.

| Outcome | Population | Study | n | RDW (%) Cn-C1 ¹ | HR (95% Cl) | p-value | Citation |
|--|--|---------------------------|--------|-------------------------------|-------------------------|---------|----------|
| Coronary heart disease (CHD) deaths, men | Adults ≥20y without diabetes or previous CV | NHANES 1988- 1994, USA | 7,201 | 1.10 | 1.19 (1.16- 1.22) | <0.001 | [36] |
| CHD deaths, women | Adults ≥20y without diabetes or previous CV | NHANES 1988- 1994, USA | 8,259 | 1.10 | 1.17 (1.13, 1.22) | <0.001 | [36] |
| All-cause mortality | Adults ≥40y | NHANES 1988- 1994, USA | 15,852 | 1.45 | 1.18 (1.14, 1.22) | <0.001 | [38] |
| All-cause mortality | Adults ≥45y | NHANES 1988- 1994, USA | 8,175 | 1.50 | 1.14 (1.10, 1.19) | <0.001 | [39] |
| Average | | | | 1.29 | 1.17 | | |
| ¹ Highest category (Cn) minus lowest C1. | | | | | | | |

It is made available under a CC-BY-NC-ND 4.0 International license .

340

| Table 5. Mortality Hazards Ratio (HR) comparing the highest (top 20-25% of individuals) and lowest categories (bottom 20-25% of individuals) in neutrophil-lymphocyte ratio (NLR). | | | | | | | | |
|--|---------------------------------------|--|--------|---------------------------|-------------------------|---------|----------|--|
| Outcome | Population | Study | n | NLR Cn-C1 ¹ | HR (95% CI) | p-value | Citation | |
| All-cause mortality | Adults ≥30y | NHANES 1999-2014, USA | 32,454 | 1.4 | 1.30 (1.21, 1.41) | <0.0001 | [6] | |
| All-cause mortality | Adults ≥45y, community dwelling | Rotterdam Study, The Netherlands | 8,715 | 1.11 | 1.56 (1.39, 1.75) | <0.001 | [44] | |
| Average | | | | 1.26 | 1.43 | | | |
| ¹ Highest category (Cn) minus lowest C1. | | | | | | | | |

341

342

Figure 1. Analytical sample flow chart. Hb, hemoglobin; NLR, neutrophil-lymphocyte ratio; RDW, red blood cell
distribution width; CRP, C-reactive protein.

345

Figure 2. A. Unadjusted red blood cell distribution width (RDW) relationship with omega-3 percentage

347 (Omega3%). Omega-3 Index (O3I) values calculated using the conversion equation [O3I = 1.2791*Omega3%+

348 1.0589 (R2=0.59; r=0.77)]. B. Unadjusted RDW relationship with the Omega-3 Index (O3I) adapted from

349 McBurney et al (22).

350

Figure 3. A. Unadjusted neutrophil-lymphocyte ratio (NLR) relationship with omega-3 percentage (Omega3%).

352 Omega-3 Index (O3I) values calculated using the conversion equation [O3I = 1.2791*Omega3%+ 1.0589

353 (R2=0.59; r=0.77)]. B. Unadjusted NLR relationship with the Omega-3 Index (O3I) adapted from McBurney et al

354 (23).







